{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T04:01:31Z","timestamp":1744689691874,"version":"3.40.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00216-025-05811-5","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T10:09:05Z","timestamp":1741946945000},"page":"2239-2252","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UPLC-Q-TOF\u2013MS\/MS and NMR studies for the structural characterization of degradation impurities of rimegepant"],"prefix":"10.1007","volume":"417","author":[{"given":"Bhuvaneshwari","family":"Vuyyala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarzan","family":"Mohanta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Ram Prasad","family":"Kollu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jithender G.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debasish","family":"Swain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"issue":"2","key":"5811_CR1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, et al. Rimegepant, an oral calcitonin gene\u2013related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142\u20139.","journal-title":"N Engl J Med"},{"issue":"10268","key":"5811_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, et al. Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51\u201360.","journal-title":"Lancet"},{"issue":"10200","key":"5811_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737\u201345.","journal-title":"Lancet"},{"key":"5811_CR4","doi-asserted-by":"crossref","unstructured":"Berger AA, et al. Rimegepant for the treatment of migraine.\u00a0Health Psychol Res. 2022;10(5): 38534.","DOI":"10.52965\/001c.38534"},{"issue":"4","key":"5811_CR5","first-page":"41","volume":"33","author":"KB Chandrasekhar","year":"2021","unstructured":"Chandrasekhar KB, Kumar H. Stability indicating analytical method development and validation for the estimation of rimegepant in bulk and its tablets using Rp-HPLC. J Pharm Res Int. 2021;33(4):41\u20139.","journal-title":"J Pharm Res Int"},{"issue":"3","key":"5811_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","volume":"4","author":"M Blessy","year":"2014","unstructured":"Blessy M, et al. Development of forced degradation and stability indicating studies of drugs\u2014a review. J Pharm Anal. 2014;4(3):159\u201365.","journal-title":"J Pharm Anal"},{"key":"5811_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.trac.2013.05.006","volume":"49","author":"S Singh","year":"2013","unstructured":"Singh S, et al. Forced degradation studies to assess the stability of drugs and products. TrAC Trends Anal Chem. 2013;49:71\u201388.","journal-title":"TrAC Trends Anal Chem"},{"issue":"1","key":"5811_CR8","first-page":"54","volume":"3","author":"R Singh","year":"2012","unstructured":"Singh R, Rehman ZU. Current trends in forced degradation study for pharmaceutical product development. J Pharm Educ Res. 2012;3(1):54.","journal-title":"J Pharm Educ Res"},{"issue":"6","key":"5811_CR9","first-page":"73","volume":"3","author":"F Iram","year":"2016","unstructured":"Iram F, et al. Forced degradation studies. J Anal Pharm Res. 2016;3(6):73.","journal-title":"J Anal Pharm Res"},{"issue":"4","key":"5811_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpba.2010.06.004","volume":"53","author":"RN Rao","year":"2010","unstructured":"Rao RN, et al. LC\u2013MS\/MS studies of ritonavir and its forced degradation products. J Pharm Biomed Anal. 2010;53(4):833\u201342.","journal-title":"J Pharm Biomed Anal"},{"key":"5811_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2024.116117","volume":"243","author":"S Chaganti","year":"2024","unstructured":"Chaganti S, et al. LC-HRMS and NMR studies for the characterization of degradation impurities of ubrogepant along with the in silico approaches for the prediction of degradation and toxicity. J Pharm Biomed Anal. 2024;243: 116117.","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"5811_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10337-023-04294-9","volume":"87","author":"R Sapkal","year":"2024","unstructured":"Sapkal R, et al. Forced degradation of an anticancer drug apalutamide: impurity profiling and structure elucidation study. Chromatographia. 2024;87(1):71\u201382.","journal-title":"Chromatographia"},{"key":"5811_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jpba.2017.01.033","volume":"138","author":"D Swain","year":"2017","unstructured":"Swain D, Samanthula G. Study on the forced degradation behaviour of ledipasvir: Identification of major degradation products using LC\u2013QTOF\u2013MS\/MS and NMR. J Pharm Biomed Anal. 2017;138:29\u201342.","journal-title":"J Pharm Biomed Anal"},{"issue":"31","key":"5811_CR14","doi-asserted-by":"publisher","first-page":"22169","DOI":"10.1039\/D4RA03952A","volume":"14","author":"SB Gopalaiah","year":"2024","unstructured":"Gopalaiah SB, Jayaseelan K. Analytical quality by design approach to develop an eco-friendly RP-HPLC method for estimation of irbesartan in chitosan polymeric nanoparticles: forced degradation studies and assessment of in vitro release mathematical modelling. RSC Adv. 2024;14(31):22169\u201384.","journal-title":"RSC Adv"},{"key":"5811_CR15","doi-asserted-by":"crossref","unstructured":"Vuyyala B, Pisini KP, Swain D. Liquid chromatography and mass spectrometric studies of gilteritinib fumarate and characterization of its major degradation products by NMR. Anal Methods. 2024;16:6856-6871.","DOI":"10.1039\/D4AY01094A"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-025-05811-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00216-025-05811-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-025-05811-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T08:36:51Z","timestamp":1744619811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00216-025-05811-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":15,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["5811"],"URL":"https:\/\/doi.org\/10.1007\/s00216-025-05811-5","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"type":"print","value":"1618-2642"},{"type":"electronic","value":"1618-2650"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}